What is the main purpose of this 8-K filing for Zoetis Inc.?

This 8-K filing announces Zoetis Inc.'s entry into a material definitive agreement to acquire Abaxis, Inc. It outlines the key terms of the Merger Agreement, including the purchase price, transaction structure, conditions to closing, and termination provisions.

What is the purchase price for Abaxis, Inc.?

Zoetis Inc. will acquire each outstanding share of Abaxis common stock for $83.00 in cash, without interest.

What are the key conditions that must be met for the acquisition to close?

The closing of the merger is contingent upon several conditions, including the approval of the Merger Agreement by a majority of Abaxis's outstanding common stock shareholders, the expiration or termination of any waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and receipt of other regulatory approvals, and the absence of any legal restraints preventing the transaction. Additionally, representations and warranties must be accurate, there must be no material adverse effect on Abaxis, and both parties must perform their obligations.

Are there any termination fees associated with this agreement?

Yes, the Merger Agreement includes termination fees. Abaxis may be required to pay a termination fee of $70,000,000 to Zoetis under certain termination conditions. Additionally, the Company (Zoetis) may owe Abaxis termination fees of $60,000,000 or $120,000,000 under specific circumstances related to the failure to obtain regulatory approvals.

ZTS 8-K: Material Agreements

Summary

Zoetis Inc. (ZTS) has announced a significant strategic move through a definitive agreement to acquire Abaxis, Inc. (ABAX) for $83.00 per share in cash, totaling an undisclosed aggregate value. This acquisition, structured as a merger, is expected to bolster Zoetis's diagnostic capabilities, a key growth area within the animal health sector. The transaction is anticipated to close, subject to customary closing conditions including regulatory approvals and shareholder consent from Abaxis. The company has outlined provisions for termination fees, with potential payments by either Zoetis or Abaxis under specific circumstances, including failure to obtain regulatory approvals or if Abaxis accepts a superior proposal. Investors should note that this filing primarily details the terms of the merger agreement, and further information regarding the transaction's strategic rationale and financial impact will be available in accompanying press releases and investor presentations. This acquisition represents a material expansion for Zoetis in the in-vitro diagnostics market for pets and livestock, aligning with its stated strategy of strengthening its portfolio through targeted M&A. The deal is subject to the usual closing conditions, including regulatory review and Abaxis shareholder approval. The inclusion of termination fees suggests a robust commitment from both parties, though it also outlines potential financial implications if the deal does not materialize under certain scenarios. Investors are encouraged to review the associated exhibits for a comprehensive understanding of the merger agreement and its potential impact on Zoetis's future growth trajectory.

Key Highlights

1Zoetis Inc. entered into a Merger Agreement to acquire Abaxis, Inc. for $83.00 per share in cash.
2The acquisition is structured as a merger where Abaxis will become a wholly owned subsidiary of Zoetis.
3The transaction is subject to customary closing conditions, including approval by Abaxis shareholders and regulatory clearances (e.g., HSR Act).
4The Merger Agreement includes provisions for termination fees payable by either party under specified circumstances.
5Zoetis aims to enhance its diagnostics portfolio through this acquisition.
6The deal completion is targeted by November 15, 2018, with potential extensions for regulatory reasons.

Zoetis Inc. 8-K Report, Material Agreement (May 16, 2018)

Summary

Key Highlights

Frequently Asked Questions